ADC Therapeutics has been granted a patent for antibodies targeting the IL13Ra2 protein, crucial for cancer treatment. The patent covers specific amino acid sequences for heavy and light chain variable regions. GlobalData’s report on ADC Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ADC Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. ADC Therapeutics's grant share as of May 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody binding to il13ra2 for medical uses
A recently granted patent (Publication Number: US11976122B2) discloses an antibody designed to bind specifically to the Interleukin-13 receptor subunit alpha-2 (IL13Ra2). The antibody, as described in the claims, features a heavy chain variable region with a specific amino acid sequence (SEQ ID NO: 3) and a light chain variable region with another specific amino acid sequence (SEQ ID NO: 4). This antibody is engineered to bind to IL13Ra2 with high affinity, competitively inhibiting the binding of other antibodies to the receptor.
Furthermore, the patent claims highlight additional features of the antibody, including its improved stability properties, lower immunogenicity in human subjects compared to other antibodies, and the option for it to be part of an antibody drug conjugate. The antibody can be conjugated to a drug moiety, such as a pyrrolobenzodiazepine dimer, to create a therapeutic agent. The patent also covers pharmaceutical compositions containing the antibody alone or as part of the antibody drug conjugate, formulated with pharmaceutically acceptable components. These claims underscore the potential of this antibody as a targeted therapeutic agent for conditions involving IL13Ra2.
To know more about GlobalData’s detailed insights on ADC Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
